549 related articles for article (PubMed ID: 33002950)
1. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.
Narain S; Berman N; Furie R
Curr Opin Rheumatol; 2020 Nov; 32(6):609-616. PubMed ID: 33002950
[TBL] [Abstract][Full Text] [Related]
2. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.
Coca A; Sanz I
Curr Opin Rheumatol; 2012 Sep; 24(5):451-6. PubMed ID: 22871954
[TBL] [Abstract][Full Text] [Related]
3. B cell depletion in lupus and Sjögren's syndrome: an update.
Coca A; Sanz I
Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
[TBL] [Abstract][Full Text] [Related]
4. Systemic Lupus Erythematosus: A Review.
Siegel CH; Sammaritano LR
JAMA; 2024 May; 331(17):1480-1491. PubMed ID: 38587826
[TBL] [Abstract][Full Text] [Related]
5. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance.
Marinho A; Delgado Alves J; Fortuna J; Faria R; Almeida I; Alves G; Araújo Correia J; Campar A; Brandão M; Crespo J; Marado D; Matos-Costa J; Oliveira S; Salvador F; Santos L; Silva F; Fernandes M; Vasconcelos C
Front Immunol; 2023; 14():1117699. PubMed ID: 37138867
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
Ebo D; DeClerck LS; Bridts CH; Stevens WJ
In Vivo; 1994; 8(4):577-80. PubMed ID: 7534494
[TBL] [Abstract][Full Text] [Related]
7. Multiple dermatofibromas in a patient with systemic lupus erythematosus and Sjögren's syndrome.
Fujisawa T; Seishima M
Mod Rheumatol; 2010 Aug; 20(4):396-400. PubMed ID: 20221662
[TBL] [Abstract][Full Text] [Related]
8. Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome.
Winzer M; Aringer M
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S156-9. PubMed ID: 21044451
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
10. Lupus Nephritis: New and Emerging Biologic and Targeted Therapies.
Kale A; Lech M; Anders HJ; Gaikwad AB
BioDrugs; 2023 Jul; 37(4):463-475. PubMed ID: 37093522
[TBL] [Abstract][Full Text] [Related]
11. Cellular targeting in autoimmunity.
Rogers JL; Serafin DS; Timoshchenko RG; Tarrant TK
Curr Allergy Asthma Rep; 2012 Dec; 12(6):495-510. PubMed ID: 23054625
[TBL] [Abstract][Full Text] [Related]
12. Biologics in Sjögren's syndrome.
Skarlis C; Marketos N; Mavragani CP
Pharmacol Res; 2019 Sep; 147():104389. PubMed ID: 31415917
[TBL] [Abstract][Full Text] [Related]
13. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
De Jesus A; Talal N
Crit Care Med; 1990 Feb; 18(2 Suppl):S132-7. PubMed ID: 2298028
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary cryptococcosis in childhood systemic lupus erythematosus and Sjögren syndrome overlap: a rare opportunistic infection.
Marques VL; Gomes RC; Viola GR; Maia MM; Durigon GS; Aikawa NE; Artur Silva C
Lupus; 2013 Nov; 22(13):1409-12. PubMed ID: 23985965
[TBL] [Abstract][Full Text] [Related]
15. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.
Idborg H; Zandian A; Sandberg AS; Nilsson B; Elvin K; Truedsson L; Sohrabian A; Rönnelid J; Mo J; Grosso G; Kvarnström M; Gunnarsson I; Lehtiö J; Nilsson P; Svenungsson E; Jakobsson PJ
Arthritis Res Ther; 2019 Feb; 21(1):62. PubMed ID: 30777133
[TBL] [Abstract][Full Text] [Related]
16. Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.
Kadavath S; Bobic S; Efthimiou P
Clin Rheumatol; 2015 Sep; 34(9):1651-2. PubMed ID: 25652332
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus and Sjögren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C.
Onishi S; Nagashima T; Kimura H; Matsuyama Y; Yoshio T; Minota S
Lupus; 2010 May; 19(6):753-5. PubMed ID: 20064909
[TBL] [Abstract][Full Text] [Related]
18. [Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].
Ampélas JF; Wattiaux MJ; Van Amerongen AP
Encephale; 2001; 27(6):588-99. PubMed ID: 11865567
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus and lupus nephritis.
Koutsokeras T; Healy T
Nat Rev Drug Discov; 2014 Mar; 13(3):173-4. PubMed ID: 24525782
[No Abstract] [Full Text] [Related]
20. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases.
Goules A; Tzioufas AG; Manousakis MN; Kirou KA; Crow MK; Routsias JG
J Autoimmun; 2006 May; 26(3):165-71. PubMed ID: 16621447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
